To determine if the selective effect of miR-126 on KRAS-Mutant cells was not restricted to CRC lines, we next transfected a panel of KRAS-WT (BxPC-3 and Hs 700T) and KRAS-Mutant (Capan-1, Capan-2, PANC-1 and MIA paca-2) pancreatic cancer cell lines with siCTL or miR-126 mimics (20 nM) and measured cell viability after 72 h. Here, KRAS is linked to pancreatic neoplasm.